{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:50:30Z","timestamp":1779313830537,"version":"3.51.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":1741,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Icatibant is used to treat acute hereditary angioedema with C1 inhibitor deficiency types I\/II (C1-INH-HAE types I\/II) and has shown promise in angioedema due to acquired C1 inhibitor deficiency (C1-INH-AAE). Data from the Icatibant Outcome Survey (IOS) were analysed to evaluate the effectiveness of icatibant in the treatment of patients with C1-INH-AAE and compare disease characteristics with those with C1-INH-HAE types I\/II. Key medical history (including prior occurrence of attacks) was recorded upon IOS enrolment. Thereafter, data were recorded retrospectively at approximately 6-month intervals during patient follow-up visits. In the icatibant-treated population, 16 patients with C1-INH-AAE had 287 attacks and 415 patients with C1-INH-HAE types I\/II had 2245 attacks. Patients with C1-INH-AAE versus C1-INH-HAE types I\/II were more often male (69 versus 42%; P\u2009=\u20090\u00b7035) and had a significantly later mean (95% confidence interval) age of symptom onset [57\u00b79 (51\u00b733\u201364\u00b753) versus 14\u00b70 (12\u00b770\u201315\u00b726) years]. Time from symptom onset to diagnosis was significantly shorter in patients with C1-INH-AAE versus C1-INH-HAE types I\/II (mean 12\u00b73 months versus 118\u00b71 months; P\u2009=\u20090\u00b7006). Patients with C1-INH-AAE showed a trend for higher occurrence of attacks involving the face (35 versus 21% of attacks; P\u2009=\u20090\u00b7064). Overall, angioedema attacks were more severe in patients with C1-INH-HAE types I\/II versus C1-INH-AAE (61 versus 40% of attacks were classified as severe to very severe; P\u2009&amp;lt;\u20090\u00b7001). Median total attack duration was 5\u00b70 h and 9\u00b70 h for patients with C1-INH-AAE versus C1-INH-HAE types I\/II, respectively.<\/jats:p>","DOI":"10.1111\/cei.12910","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T09:10:09Z","timestamp":1481361009000},"page":"148-153","source":"Crossref","is-referenced-by-count":32,"title":["Comparing acquired angioedema with hereditary angioedema (types I\/II): findings from the Icatibant Outcome Survey"],"prefix":"10.1093","volume":"188","author":[{"given":"H J","family":"Longhurst","sequence":"first","affiliation":[{"name":"Department of Immunology, Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Zanichelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Luigi Sacco Hospital Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3005-9858","authenticated-orcid":false,"given":"T","family":"Caballero","sequence":"additional","affiliation":[{"name":"Department of Allergy, Hospital La Paz Institute of Health Research (IdiPaz), Biomedical Research Network on Rare Diseases (CIBERER, U754), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Bouillet","sequence":"additional","affiliation":[{"name":"National Reference Centre for Angioedema, Internal Medicine Department, Grenoble University Hospital, Grenoble, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Aberer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Allergie-Centrum-Charit\u00e9, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Fain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, DHU i2B, Saint Antoine Hospital, University Paris 6, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Fabien","sequence":"additional","affiliation":[{"name":"Shire, Zug, Switzerland at the time of data analysis. Now with Vifor Pharma, Glattbrugg, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Andresen","sequence":"additional","affiliation":[{"name":"Shire, Zug, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"2021120808031688800_cei12910-bib-0001","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.anai.2012.10.008","article-title":"International consensus on hereditary and acquired angioedema","volume":"109","author":"Lang","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2021120808031688800_cei12910-bib-0002","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/WOX.0b013e318279affa","article-title":"WAO guideline for the management of hereditary angioedema","volume":"5","author":"Craig","year":"2012","journal-title":"World Allergy Organ J"},{"key":"2021120808031688800_cei12910-bib-0003","first-page":"313","article-title":"New perspectives in acquired angioedema","volume":"16","author":"Kivity","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"2021120808031688800_cei12910-bib-0004","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.critrevonc.2013.02.004","article-title":"Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship","volume":"87","author":"Castelli","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021120808031688800_cei12910-bib-0005","first-page":"165","article-title":"Rituximab therapy in a patient with low grade B-cell lymphoproliferative disease and concomitant acquired angioedema","volume":"7","author":"Kaur","year":"2014","journal-title":"J Asthma Allergy"},{"key":"2021120808031688800_cei12910-bib-0006","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2340\/00015555-1157","article-title":"Acquired angioedema responding to rituximab","volume":"91","author":"Hassan","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"2021120808031688800_cei12910-bib-0007","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/all.12380","article-title":"Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group","volume":"69","author":"Cicardi","year":"2014","journal-title":"Allergy"},{"key":"2021120808031688800_cei12910-bib-0008","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1398-9995.2011.02751.x","article-title":"Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group","volume":"67","author":"Cicardi","year":"2012","journal-title":"Allergy"},{"key":"2021120808031688800_cei12910-bib-0009","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1710-1492-6-14","article-title":"Acquired angioedema","volume":"6","author":"Cicardi","year":"2010","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2021120808031688800_cei12910-bib-0010","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1398-9995.2012.02853.x","article-title":"Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study","volume":"67","author":"Zanichelli","year":"2012","journal-title":"Allergy"},{"key":"2021120808031688800_cei12910-bib-0011","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2500\/aap.2013.34.3620","article-title":"Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency","volume":"34","author":"Patel","year":"2013","journal-title":"Allergy Asthma Proc"},{"key":"2021120808031688800_cei12910-bib-0012","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1684\/ejd.2013.2252","article-title":"Use of recombinant C1 inhibitor in patients with resistant or frequent attacks of hereditary or acquired angioedema","volume":"24","author":"Manson","year":"2014","journal-title":"Eur J Dermatol"},{"key":"2021120808031688800_cei12910-bib-0013","doi-asserted-by":"crossref","first-page":"e53773","DOI":"10.1371\/journal.pone.0053773","article-title":"Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment","volume":"8","author":"Maurer","year":"2013","journal-title":"PLOS ONE"},{"key":"2021120808031688800_cei12910-bib-0014","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/joim.12304","article-title":"Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients","volume":"277","author":"Mansi","year":"2015","journal-title":"J Intern Med"},{"key":"2021120808031688800_cei12910-bib-0015","first-page":"28","article-title":"Diagnosis and management of hereditary angioedema","volume":"111","author":"Johnston","year":"2011","journal-title":"J Am Osteopath Assoc"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12910","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/188\/1\/148\/41643163\/cei12910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/188\/1\/148\/41643163\/cei12910.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:27:37Z","timestamp":1641054457000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/188\/1\/148\/6411959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,9]]},"published-print":{"date-parts":[[2017,3,9]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12910","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,4]]},"published":{"date-parts":[[2017,2,9]]}}}